Physician profile
Samuel A Smith
NPI 1043399876
$3,209.04
in general payments reported to CMS, 2019-2025
21 companies · $458 in 2025
The $458 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $185 · 2021: $349 · 2022: $338 · 2023: $517 · 2024: $789 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,763.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $697.76 | 2019-2024 | Jornay Pm |
| Corium, LLC | $472.60 | 2022-2025 | Azstarys |
| Sanofi Pasteur INC. | $335.32 | 2019-2025 | |
| Tris Pharma INC | $274.36 | 2019-2023 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $268.76 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $253.92 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Collegium Pharmaceutical, INC. | $244.98 | 2025 | Jornay Pm |
| Pfizer INC. | $142.39 | 2019-2025 | |
| Neos Therapeutics, LP | $141.28 | 2019-2020 | |
| Glaxosmithkline, LLC. | $120.31 | 2019-2023 | Bexsero, Pediarix |
| Supernus Pharmaceuticals, INC. | $53.37 | 2021 | |
| Genentech USA, INC. | $33.53 | 2019 | |
| Shire North American Group INC | $26.21 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $26.14 | 2023 | |
| Sobi, INC | $23.76 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $22.00 | 2024 | |
| Seqirus USA INC | $18.28 | 2024 | Flucelvax |
| Astrazeneca Pharmaceuticals LP | $16.62 | 2023 | Flumist Quadrivalent |
| Mission Pharmacal Company | $13.35 | 2019 | |
| Kaleo, INC. | $12.82 | 2022 | |
| Adlon Therapeutics L.P. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.